Betagistin

General characteristics. Structure:

Active agent: 24 mg of a betagistin of dihydrochloride (betagistin of a hydrochloride).

Excipients: cellulose microcrystallic – 199,2 mg, lactoses monohydrate – 120 mg, citric acid monohydrate – 7,5 mg, silicon dioxide colloid (aerosil) – 11,25 mg, talc – 9,3 mg, calcium stearate – 3,75 mg.

Pharmacological properties:

Pharmacodynamics. Betagistin affects mainly histamine N1-and H3 receptors of an inner ear and vestibular nuclei of the central nervous system. By the direct agonistic (stimulating) impact on H1 receptors of vessels of an inner ear, and also indirectly through impact on H3 receptors improves microcirculation and permeability of capillaries, normalizes endolymph pressure in a labyrinth and a snail. At the same time бетагистин increases a blood stream in a basilar artery.

Has the expressed central effect, being H3 receptors inhibitor of kernels of a vestibular nerve. Improves conductivity in neurons of vestibular nuclei at the level of a brain trunk.

Reduces the frequency and intensity of dizziness, reduces a sonitus, improves hearing at its decrease.

The stable therapeutic effect occurs in 14 days.

Pharmacokinetics. Communication with proteins of a blood plasma – low is absorbed completely after intake. Time of achievement maximum concentration in a blood plasma - 3 hours. It is almost completely removed by kidneys in the form of a metabolite (2-pyridylacetic acid) within 24 hours. An elimination half-life - 3-4 hours.

Indications to use:

- treatment of vestibular dizziness of various origin;
- a disease and Menyer's syndrome including symptoms: dizziness (is followed by nausea/vomiting), a headache, a sonitus, the progressing decrease in hearing.

Route of administration and doses:

Inside, during food on 1 tablet of drug Betagistin 2 times a day. The dose of drug and duration of reception are selected individually depending on reaction of the patient to the carried-out therapy.

Improvement of a state is noted already at the beginning of a therapy course, the stable therapeutic effect occurs after 2-3 weeks of treatment.

Features of use:

The therapeutic effect in some cases increases within several months from the beginning of therapy.

Impact on ability to drive the car and the equipment. Betagistin does not influence ability to manage motor transport or to be engaged in the types of activity demanding speed of psychomotor reactions.

Use at pregnancy and in the period of a lactation. There are not enough data for assessment of a possibility of use of drug at pregnancy and in the period of a lactation. In this regard administration of drug Betagistin is not recommended at pregnancy. If administration of drug is necessary in the period of a lactation, breastfeeding needs to be stopped.

Side effects:

Allergic reactions: skin rash, itch, small tortoiseshell, Quincke's edema.

From digestive tract: nausea, pains in epigastric area (which disappear at administration of drug along with meal or at a dose decline).

If any of the side effects specified in the instruction are aggravated, or you noticed any other side effects which are not specified in the instruction, report about it to the doctor.

Interaction with other medicines:

Cases of interaction or incompatibility with other medicines are unknown.

Contraindications:

- hypersensitivity to any of drug components;
- lactose intolerance; deficit of lactase; glyukozo-galaktozny malabsorption;
- age up to 18 years (efficiency and safety are not established);
- pregnancy and period of a lactation.

With care. A peptic ulcer of a stomach and duodenum (in the anamnesis), a pheochromocytoma, bronchial asthma.

Overdose:

Symptoms: nausea, vomiting, spasms. Treatment: symptomatic therapy.

Storage conditions:

In the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity 2 years. Not to use after a period of validity.

Issue conditions:

According to the recipe

Packaging:

Tablets on 24 mg. 10 or 15 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil. 1, 2, 3, 5 or 6 blister strip packagings on 10 tablets or 2 or 4 blister strip packagings on 15 tablets together with the application instruction in a pack from a cardboard.